Aprepitant: A New Modality for the Prevention of Postoperative Nausea and Vomiting: An Evidence-Based Review

Milnes, Vania; A, González; Amos, Veronica

doi:10.1016/j.jopan.2014.11.013

Cited by 25 publications

(24 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For ethical reasons, this study did not include a control group that would receive a placebo, and the total incidence of PON and POV remains only at prediction level. The total expected incidence of PON calculated by a simplified Apfel score was about 40% [6]. In our study, the total incidence of PON amounts to 12.7%, incidence of PON in the group receiving combined therapy was 10.74%, and in the group receiving monotherapy, it was 14.75%.…”

Section: Discussionmentioning

confidence: 40%

“…This is significant information, because both of these characteristics are listed in literature as predictive factors in the occurrence of PONV. Non-smoker status is known in literature as an independent predictor of occurrence of PONV [6]. Over the past 15 years, research has proven that nonsmoker status reduces the likelihood of PONV by 34%.…”

Section: Discussionmentioning

confidence: 99%

“…1. patient related factors (female sex, age, positive anamnesis for PONV, kinetosis, non-smoker status, the patient's American Society of Anesthesiologists (ASA) status, positive anamnesis for migraine, menstrual cycle phase); 2. surgery related factors (length of surgery, type of surgery); 3. anesthesia related factors (inhalation anesthetics, intravenous anesthetics, opioids, muscle block reversal, anesthetic technique and N 2 O); 4. early postoperative period related factor (pain, opioid administration, postoperative movement of patients, early fluid and food ingestion and hypotension) [6]. The most used antiemetic drugs used in PONV prevention and therapy include dopamine receptor antagonists, serotonin 5-HT 3 receptor antagonists, and corticosteroids [7,8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dexasone and metoclopramide vs. granisetron in the prevention of postoperative nausea and vomiting

Bagi¹,

Bagi²,

Bagi³

et al. 2019

Srp Arh Celok Lek

View full text Add to dashboard Cite

Introduction Postoperative nausea and vomiting (PONV) is one of the most common postoperative complications. The incidence in adult population is 20-30%, and it can be up to 80% in high-risk population such as gynecological and laparoscopic surgeries. The objective of this study is to compare the efficiency of the combination therapy in comparison with monotherapy in the prevention of PONV in gynecological and laparoscopic surgeries. Methods An observational prospective cohort study was conducted on a sample of 64 patients (32 patients per group) treated postoperatively at the Gynecology and Obstetrics Ward of GH Subotica, in the period from January-March 2017. The anesthesiologist in charge administered the combination of dexasone and metoclopramide or granisetron in monotherapy according to protocol to patients for prevention of PONV. Results The demographic characteristics of patients are homogenous and show a statistically significant difference only in the characteristics of length of smoker status and maximum intra-abdominal pressure during surgery. The total incidence of postoperative nausea in the fifth, 15th and 60th minute was 15.6%, 17.2% and 18.7% respectively, and in the fourth, eighth, 12th, and 24th postoperative hour it was 12.5%, 7.8%, 10.9%, and 6.2%, respectively. The incidence of postoperative vomiting in the fifth, 15th, and 60th minute was 1.6%, 4.7%, and 4.7%, respectively, and in the fourth, eighth, 12th, and 24th postoperative hour it was 1.6%, 3.2%, 1.6%, and 1.6%, respectively. Conclusion The study proved that the combination effect of dexasone and metoclopramide is not inferior compared to monotherapy with granisetron.

show abstract

Section: Discussionmentioning

confidence: 40%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dexasone and metoclopramide vs. granisetron in the prevention of postoperative nausea and vomiting

Bagi¹,

Bagi²,

Bagi³

et al. 2019

Srp Arh Celok Lek

View full text Add to dashboard Cite

show abstract

“…There have been several large prospective randomized clinical trials investigating the role of NK1R antagonists as antidepressants, with mixed results (29). There is strong evidence accumulating recently from a large number of prospective randomized controlled clinical trials showing efficiency of NK1R inhibitors in postoperative nausea and vomiting in both adults and children for a large variety of different surgeries (30)(31)(32)(33)(34)(35)(36). No NK1R antagonist to date is approved specifically for cancer therapy, and there are currently no ongoing clinical trials that assess their therapeutic potential regarding cancer.…”

Section: Therapeutic Innovations In Neuroblastomamentioning

confidence: 99%

Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System

Berger

Schweinitz

2017

View full text Add to dashboard Cite

“…6,9,10 NK-1 RAs have high affinity and selectivity in the prophylaxis of emesis. [11][12][13] Aprepitant is a potent and selective substance P (NK1receptor) antagonist that is recommended in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic and moderately emetogenic cancer chemotherapy (HEC and MEC, respectively). 12,[14][15][16] The pharmacokinetics (PK) of aprepitant have been well characterized in the non-Chinese population, and several multi-center studies have shown the efficacy and tolerability of aprepitant in Chinese subjects.…”

Section: Introductionmentioning

confidence: 99%

<p>Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects</p>

Yang¹,

Xu²,

Li³

et al. 2020

DDDT

View full text Add to dashboard Cite

Purpose: Aprepitant is used to prevent nausea and vomiting associated with moderately and highly emetogenic chemotherapy. In this open-label, 2-period study, the safety, tolerability, and pharmacokinetics (PK) of aprepitant (EMEND ® ) were evaluated in healthy Chinese and Caucasian subjects. Patients and Methods: Twelve Chinese and 12 Caucasian subjects were to receive a 125 mg single-dose of aprepitant during period 1; subsequently, after 15 days washout, only Chinese subjects were to receive the 3-day regimen in period 2. In each period, serial blood samples were collected and analyzed by a validated liquid chromatographic and mass spectrometric method to characterize aprepitant PK across both groups. Results: In both Chinese and Caucasian subjects, there were no serious adverse events. AUC 0-∞ , C max , T max, and t 1/2 were largely comparable between the two ethnicities. Comparing the result of period 1 in Chinese and Caucasian subjects, the geometric leastsquares mean maximum plasma concentrations (C max ) were 1482 ng/mL and 1435 ng/mL, and the area under the concentration-time curve (AUC 0-∞ ) 34,035 hr·ng/mL and 34,188 hr·ng/mL. In period 2, the geometric mean AUC 0-24 on Day 1 and Day 3 were 19,446 hr·ng/ mL and 27,843 hr·ng/mL, and the geometric mean C max on Day 1 and Day 3 were 1423 ng/ mL and 1757 ng/mL, respectively. Conclusion: Aprepitant is generally safe and well tolerated in healthy Chinese and Caucasian subjects. Aprepitant PK is comparable between Chinese and Caucasian subjects following single-dose administration. The PK following a clinical 3-day regimen on healthy Chinese subjects has been characterized.

show abstract

Aprepitant: A New Modality for the Prevention of Postoperative Nausea and Vomiting: An Evidence-Based Review

Cited by 25 publications

References 14 publications

Dexasone and metoclopramide vs. granisetron in the prevention of postoperative nausea and vomiting

Dexasone and metoclopramide vs. granisetron in the prevention of postoperative nausea and vomiting

Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System

<p>Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects</p>

Contact Info

Product

Resources

About